Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Guadecitabine - Astex Pharmaceuticals

Drug Profile

Guadecitabine - Astex Pharmaceuticals

Alternative Names: Decitabine deoxyguanosine; Decitabine deoxyguanosine dinucleotide; DNMT-inhibitor-SGI-110; Guadecitabine-sodium; S-110; SGI-110

Latest Information Update: 04 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SuperGen
  • Developer Astex Pharmaceuticals; AstraZeneca; Big Ten Cancer Research Consortium; Fox Chase Cancer Center; Indiana University School of Medicine; John Hopkins University; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); University of Southern California; Weill Cornell Medical College
  • Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Furans; Purine nucleosides; Small molecules; Triazines
  • Mechanism of Action Antimetabolites; DNA cytosine 5 methyltransferase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Gastrointestinal stromal tumours; Liver cancer; Myeloproliferative disorders; Ovarian cancer; Phaeochromocytoma; Renal cell carcinoma; Small cell lung cancer; Solid tumours; T-cell lymphoma; Urogenital cancer
  • Phase I/II Bladder cancer; Colorectal cancer; Renal cancer
  • Phase I Cholangiocarcinoma; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer
  • No development reported Germ cell and embryonal neoplasms

Most Recent Events

  • 15 Jun 2019 Efficacy and adverse events data from the phase III ASTRAL-1 trial in Acute myeloid leukaemia presented at the 24th Congress of the European Haematology Association (EHA-2019)
  • 11 Jun 2019 Guadecitabine is still in phase I trial in Italy (Astex Pharmaceuticals, pipeline June 2019)
  • 10 Jun 2019 Taiho Pharmaceutical will commercialise guadecitabine in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top